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Abstract. Yellow fever (YF) vaccine-associated serious adverse events and changing YF epidemiology have challenged
healthcare providers to vaccinate only travelers whose risk of YF during travel is greater than their risk of adverse events.
We describe the travel characteristics and YF vaccine use among US travelers visiting Global TravEpiNet clinics from
January of 2009 to March of 2011. Of 16,660 travelers, 5,588 (34%) had itineraries to areas with risk of YF virus
transmission. Of those travelers visiting one country with YF risk (N = 4,517), 71% were vaccinated at the visit, and 20%
were presumed to be immune from prior vaccination. However, travelers visiting friends and relatives (odds ratio [OR] =
2.57, 95% confidence interval [95% CI] = 1.27–5.22) or going to Nigeria (OR = 3.01, 95%CI = 1.37–6.62) were significantly
more likely to decline vaccination. To optimize YF vaccine use, clinicians should discuss an individual’s risk–benefit
assessment of vaccination and close knowledge gaps regarding vaccine use among at-risk populations.
INTRODUCTION
Yellow fever (YF) is caused by infection with a flavivirus
(family Flaviviridae) that is transmitted to humans primarily
through the bite of Haemagogus spp. and Aedes spp. mosqui-
toes in South America and Africa, respectively. YF virus
infection can be asymptomatic or cause a spectrum of disease
ranging from a mild non-specific febrile illness to hemor-
rhagic fever with multiorgan failure and death. The number
of YF cases reported widely varies, with approximately 50–
5,000 cases per year.1 However, this estimate is likely an
underestimate of the true number of cases, because only a
limited percentage of cases are identified because of under-
diagnosis and underreporting.2
The epidemiology of YF continues to change, which is
evidenced by a recent outbreak in Paraguay in 2008 and an
increase in reported cases in Central and East Africa in 2010–
2012.3–6 Travel to countries with emerging economies, includ-
ing nations where YF is endemic, has become more common,
increasing from 31% of international tourist arrivals in 1990
to 47% in 2010.7 Specifically, many popular destinations in
South America and sub-Saharan Africa include areas with
risk of YF virus transmission (i.e., areas endemic or partially
endemic for YF).
Prevention of YF in travelers is critical, because no specific
treatment of YF disease exists. Effective prevention strategies
include the use of personal protective measures, such as insect
repellent on skin and clothing, staying in accommodations
with screens or air conditioning, and vaccination. The YF
17D vaccine has historically been considered one of the safest
vaccines, with more than 500 million doses delivered globally.1
However, reports of serious adverse events have been asso-
ciated with the vaccine, including YF vaccine-associated
neurologic disease (YEL-AND) and more recently, YF vaccine-
associated viscerotropic disease (YEL-AVD).8 YEL-AVD
results from the replication and dissemination of YF vaccine
virus, producing a clinical syndrome similar to wild-type YF
disease; it is fatal in approximately 65% of cases.2 Although
reporting rates of both YEL-AND and YEL-AVD are higher
in selected populations, young healthy adults have also devel-
oped these serious adverse events.8,9 Because of these safety
concerns, it is essential that healthcare providers vaccinate
only those travelers whose risk of YF during travel is esti-
mated to be greater than their risk of serious adverse events
from vaccination.2
The objective of this study was to describe the characteris-
tics of US travelers planning to visit countries with risk of YF
virus transmission and YF vaccine usage. Specifically, we
analyzed the demographics, itineraries, and YF vaccine use
among travelers to countries with risk of YF virus trans-
mission who visited Global TravEpiNet (GTEN) providers
for pre-travel consultations.
METHODS
GTEN is a consortium of US travel health practices;
a detailed description of the consortium was published previ-
ously.10 Enrollment of clinics and patients in GTEN began
in January of 2009 and is ongoing; this analysis uses data
collected from January of 2009 to March 31, 2011. Of note,
these data were collected before the release of the revised
2012 YF vaccine recommendation maps for international
travelers on April 1, 2011.11–13 The types of the GTEN prac-
tices include academic practices, health maintenance organi-
zations, private practices, pharmacy-based practices, and
public health clinics. All GTEN consortium members are
designated YF vaccine administration sites. An institutional
review board at each participating site reviewed and approved
analyses of the data.
We used an online tool to collect data routinely recorded
on all individuals seen for pre-travel consultations in GTEN
clinics. No personal identifiers were collected. For each con-
sultation, travelers self-reported medical history, travel itiner-
ary details, reasons for seeking pre-travel advice, and purpose
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of travel (e.g., leisure, business, returning to country of origin of
self or family to visit friends and relatives, research/education,
or non-medical service work). Multiple responses were allowed
for some variables, including purpose of travel, reasons for
seeking pre-travel consultation, and destination.
GTEN healthcare providers verified traveler responses and
entered information into the tool about vaccination history,
vaccines administered (including YF vaccine), medications
prescribed, and travel health advice provided during the clinic
visit. If YF vaccine was not administered to travelers visiting
areas with risk of YF virus transmission, the tool prompted
healthcare providers to give a reason; available options
included pre-existing immunity, vaccine not indicated, referred
to primary care provider for vaccination, patient declined,
medical contraindication, insufficient time, or vaccine not
available. Pre-existing immunity to YF virus was defined as
self-reported vaccination within the 10 years before the current
clinic visit; evidence of previous vaccination usually involved
presentation of a YF vaccination certificate, but no serologic
tests were performed to confirm immunity.
We used the 2009–2010 US Centers for Disease Control
and Prevention (CDC) YF maps to identify countries classi-
fied as either entirely or partially endemic.14 Travelers going to
destinations with risk for YF virus transmission were defined as
those travelers visiting countries considered entirely endemic
(and therefore, YF vaccine was always recommended) and/or
countries considered partially endemic, for which the provider
noted that YF vaccine was indicated by the traveler’s stated
itinerary. Hence, travelers going to partially endemic countries
and for whom the provider chose vaccination not indicated for
this itinerary were excluded from analyses. Travelers who
selected returning to country of origin of self or family to visit
friends and relatives (VFR) and who were visiting at least one
low or low–middle income country according to the 2009
World Bank World Development Report (available at: http://
econ.worldbank.org) were further defined as VFR travelers as
described by the CDC.11,15
The demographics, travel characteristics, vaccination sta-
tus, and contraindications were characterized for GTEN trav-
elers visiting areas with risk for YF virus transmission. If the
Table 1
Demographic and travel characteristics of US Global TravEpiNet travelers visiting countries with risk of YF virus transmission
Characteristics Total
Travel to
South America only* Africa only Both
Total (row %) 5,588 1,734 (31) 3,773 (68) 81 (1)
Age (n, column %)
£ 9 months 19 (< 1) 1 (< 1) 18 (< 1) 0 (0)
10 months to 12 years 426 (8) 71 (4) 350 (9) 5 (6)
13–18 years 280 (5) 93 (5) 185 (5) 2 (2)
19–59 years 4,047 (72) 1,238 (71) 2,747 (73) 62 (77)
60–69 years 615 (11) 245 (14) 362 (10) 8 (10)
70–79 years 175 (3) 71 (4) 100 (3) 4 (5)
> 80 years 26 (< 1) 15 (1) 11 (< 1) 0 (0)
Sex (n, column %)
Female 3,101 (55) 914 (53) 2,142 (57) 45 (56)
Male 2,487 (45) 820 (47) 1,631 (43) 36 (44)
Reason for seeking pre-travel health advice†‡ (n, column %)
Referral from primary care physician 760 (19) 208 (17) 540 (20) 12 (19)
Read information on the internet 465 (12) 170 (14) 285 (10) 10 (16)
Travel agent suggested making the appointment 254 (6) 75 (6) 179 (6) 0 (0)
Employer suggested making the appointment 390 (10) 92 (8) 286 (10) 12 (19)
Family member or friend suggested making the appointment 641 (16) 195 (16) 436 (16) 10 (16)
Public health announcement prompted scheduling appointment 35 (< 1) 13 (1) 22 (1) 0 (0)
Concern about health issues related to travel 1,293 (32) 390 (32) 876 (32) 27 (44)
Type of destination† (n, column %)
Urban 4,984 (89) 1,599 (92) 3,304 (88) 81 (100)
Rural 4,216 (75) 1,401 (81) 2,758 (73) 57 (70)
Type of accommodation† (n, column %)
Camping 533 (10) 183 (11) 330 (9) 20 (25)
Dormitory or hostel 979 (18) 360 (21) 596 (16) 23 (28)
Home stay with relatives 1,137 (20) 170 (10) 962 (26) 5 (6)
Home stay with non-relatives 782 (14) 278 (16) 481 (13) 23 (28)
Hotel 3,512 (63) 1,295 (75) 2,147 (57) 70 (86)
Other 903 (16) 249 (14) 638 (17) 16 (20)
Top three purposes of travel† (n, column %)
Leisure§ 2,976 (53) 1,245 (72) 1,684 (45) 47 (58)
VFR§¶ 887 (16) 64 (4) 819 (22) 4 (5)
Business§ 827 (15) 202 (12) 602 (16) 23 (28)
Travelers include those travelers visiting countries where the entire country is considered endemic and/or travelers visiting countries considered partially endemic where the healthcare provider
noted that vaccine was indicated. Individuals going to partially endemic countries where the healthcare provider chose vaccination not indicated for this itinerary were excluded. Data were
collected from January of 2009 to March 31, 2011.
*South America includes the Central American country of Panama and the Caribbean islands of Trinidad and Tobago.
†Travelers could choose more than one answer.
‡The question regarding the traveler’s reason for seeking travel advice is not a required field; there are 1,549 missing values for this question.
§More travelers to Africa indicated VFR (22% versus 4%, P < 0.0001) and business (16% versus 12%, P < 0.0001) than travelers to South America; however, more travelers indicated leisure to
South America than Africa (72% versus 45%, P < 0.0001). Comparisons were made by looking at travelers to Africa only or South America only and whether they indicated leisure travel versus
any other type of travel, whether they indicated VFR versus any other type of travel, and whether they indicated business travel versus any other type of travel.
¶Travelers participating in GTEN who selected returning to country of origin of self or family to visit friends and relatives and were visiting low or low–middle income countries according to the
2009 World Bank World Development Report (available at http://econ.worldbank.org) were termed VFR travelers as defined previously by the CDC. Travelers choosing returning to country of
origin of self or family to visit friends and relatives but who did not meet the criteria for visiting low or low–middle income countries included travelers to Venezuela (N = 2), Panama (N = 2), Brazil
(N = 35), Argentina (N = 2), Gabon (N = 2), and Equatorial Guinea (N = 1).
GTEN TRAVELERS TO AREAS WITH RISK OF YF 955
healthcare provider specified that vaccine was contra-
indicated, the traveler’s medical history was reviewed for a
clinical reason, because the tool did not prompt the provider
to denote the condition(s) that contraindicated the vaccine.
Using the list of contraindications and precautions to YF vac-
cine designated by the Advisory Committee on Immunization
Practices (ACIP) in 2010, we inferred from the patient’s med-
ical history the potential clinical reasons why the provider
determined the vaccine was contraindicated.2
Two-sided c2 tests of independence were used for categor-
ical comparisons. Bivariate and multivariable logistic regres-
sions were used to evaluate the association of age, sex,
purpose of travel, duration of travel, destinations, and type of
destination with whether travelers declined or received YF
vaccination. Regression analyses were limited to travelers
only listing one destination country, listing one purpose of
travel, and declining or administered vaccine at the clinic visit.
Because of possible between-clinic variation, random inter-
cept models with clinic site as the random effect were used in
both the bivariate and multivariable regressions. A correction
was also made to reduce bias because of small numbers of
clusters (clinic sites).16 A two-sided P value < 0.05 was consid-
ered to be significant. All statistical analyses were performed
using SAS 9.2 (SAS Institute Inc., Cary, NC).
RESULTS
Demographics and travel characteristics of GTEN travelers
visiting areas with risk for YF virus transmission. Of 16,660
total GTEN travelers, 5,588 (34%) had itineraries that
included travel to an area with risk for YF virus transmission.
Table 1 outlines the demographic and travel characteristics
of those 5,588 travelers; 19 (< 1%) were £ 9 months of age,
816 (15%) were ³ 60 years of age, and more than one-half
(55%) were women. The two most frequent reasons travelers
selected for seeking pre-travel consultations were concern
about health issues related to travel (32%) and referral from
their primary care physician (19%). Thirty-one percent of trav-
elers planned to visit South America only, 68% were visiting
Africa only, and 1% planned to visit both continents. Travelers
Figure 1. Top travel destinations among US Global TravEpiNet travelers visiting countries with risk of YF virus transmission in 2009–2011
(country [% of trips]). The map is the YF risk map that was available to clinicians during the period of data collection described in this analysis
(January of 2009 to March 31, 2011). Top travel destinations for travelers included persons traveling to more than one country. The total number
of trips for travelers going to areas with risk of YF virus transmission was 7,081. For all YF-endemic countries for which no labels and percentages
are listed, the percentages of all travelers’ trips are £ 1%.
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to both South America and Africa reported that they were
visiting both urban and rural areas (89% and 75%, respectively).
Most travelers reported that they were spending some or the
entire trip in hotels (63%), although among travelers to Africa,
26% were spending some or their entire trip in a home with
relatives. The top three purposes of travel were leisure (53%),
VFR (16%), and business (15%). There were more travelers
to Africa who indicated VFR or business than travelers to
South America (22% versus 4%, P < 0.0001; 16% versus 12%,
P < 0.0001); however, more travelers indicated leisure trips to
South America than Africa (72% versus 45%, P < 0.0001).
The top travel destinations of GTEN travelers visiting
countries with risk of YF transmission are shown in Figure 1.
The 10 most common destinations, in descending order, were
Kenya, Tanzania, Ghana, Peru, Brazil, Argentina, Uganda,
Ethiopia, Ecuador, and Nigeria. Of 5,588 total travelers to
YF-endemic countries, 4,396 (79%) were traveling to at least 1
of these 10 destination countries. Leisure travel was the most
common purpose for travel for these travelers. However, 42%
of travelers to Ethiopia and 40% of travelers to Nigeria indi-
cated VFR as their purpose of travel (Figure 2). Other com-
mon purposes of travel included business (Kenya, Brazil, and
Uganda), research/education (Argentina, Uganda, and Ecuador),
and adventure (Tanzania and Peru).
YF vaccination status of GTEN travelers. Among all trav-
elers going to entirely endemic or partially endemic countries,
90% and 93% of travelers, respectively, received vaccination at
the current clinic visit or were presumed to have pre-existing
immunity based on reported YF vaccination within the last
10 years (Table 2). Of all 3,207 travelers receiving vaccine at
the clinic visit, only 149 (5% overall) reported having been
vaccinated more than 10 years before. Seventeen travelers,
eight to entirely endemic and nine to partially endemic areas,
were referred to another provider for vaccination. For 34 trav-
elers, vaccine was reportedly not available at the time of their
clinic visit.
Of those travelers visiting 1 of the top 10 most commonly
visited countries with risk of YF virus transmission, the highest
proportion of immune travelers (vaccinated at the visit or had
pre-existing immunity) was traveling to Ghana (96%) and
Uganda (96%). The highest proportions of non-immune trav-
elers who were not vaccinated before their current trips were
individuals planning travel to Ethiopia and Nigeria (22% and
16%, respectively); the most common reason reported for not
vaccinating was that the traveler declined vaccination (Table 2).
Among all travelers to entirely endemic countries who declined
vaccination, almost one-half (45%) planned travel to either
Ethiopia orNigeria.
Providers reported that vaccine was contraindicated for
110 (2%) of all travelers visiting areas of YF virus transmission
(Table 3). The most commonly reported medical conditions
in these travelers were cancer (17%); immune-suppressing
Figure 2. Purposes of travel to the top 10 destination countries of US Global TravEpiNet travelers visiting areas with risk of YF virus
transmission. Travelers who included only one purpose of travel and traveled to at least one of the top 10 countries included in the graph (N =
4,116) are shown. Travelers who identified only one purpose of travel represented 78% of the dataset (4,379/5,588). Of 5,588 total travelers, 4,396
(79%) were traveling to at least one of these 10 destination countries. Travelers participating in GTEN who selected returning to country of origin
of self or family to visit friends and relatives and were visiting low or low–middle income countries according to the 2009 World Bank World
Development Report (available at http://econ.worldbank.org) were termed VFR travelers as defined previously by the CDC. Other activities
includes self-described other activities, attending gatherings, military, receiving medical care, or adoption.
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medication/chemotherapy or steroids by mouth in the last
3 months (17%); other immune system issue (12%); or age
less than 6 months (9%).
Comparison of travelers who declined with travelers who
received YF vaccine. Table 4 outlines both the bivariate and
multivariable comparisons of the demographic and travel
characteristics of travelers who declined or were administered
YF vaccination. Travelers to either Ethiopia or Nigeria were
included to assess whether they still were more likely to
decline than those travelers going to other countries after the
data were controlled for all other variables. Specifically, trav-
elers to Ethiopia were compared with travelers going to coun-
tries other than Ethiopia and Nigeria. Similarly, travelers to
Nigeria were compared with travelers going to countries other
than Nigeria and Ethiopia. Furthermore, leisure travelers and
VFRs were compared separately with those travelers travel-
ing for other reasons. In the multivariable model, there was
significant variance attributed by clinic differences on the
outcome of receiving or declining YF vaccine (variance =
1.46, standard error = 0.64, P = 0.035). Adjusting for all other
variables in the model, males were less likely to decline vac-
cine than females (odds ratio [OR] = 0.633, 95% confidence
interval [CI] = 0.41–0.99). VFRs were significantly more likely
to decline YF vaccination than receive it compared with
non-VFR/non-leisure travelers (OR = 2.57, 95% CI = 1.27–
5.22). Finally, travelers to Nigeria were 3.01 (95% CI = 1.37–
6.62) times more likely to decline vaccination than receive
vaccination compared with travelers to other countries.
DISCUSSION
Our study found that approximately one-third of GTEN
travelers were visiting areas with risk of YF virus transmis-
sion; most (> 90%) were vaccinated at their pre-travel health
consultation or reported YF vaccination within the past
10 years. We also found that VFR travelers behave differently
than those travelers traveling for other purposes with regard
to acceptance of YF vaccination. Furthermore, travelers to
Nigeria and females were also more likely to decline vaccine.
Few published studies have focused on the pre-travel prep-
aration of travelers going to areas with risk of YF virus trans-
mission; however, the prevalence of YF vaccination in our
study was higher (> 90%) than the prevalence described in an
airport study in South Africa, in which only 76% of travelers to
YF risk areas could produce proof of vaccination.17 Another
study comparing VFR travelers with tourist travelers found
that 90% of adult tourists were vaccinated against YF virus
compared with 66% of adult VFR travelers.18
Previous studies have found that VFR populations are less
likely to seek care than those travelers traveling for other
purposes and are at greater risk for acquiring diseases while
abroad.18–21 In this study, VFR travelers who did seek pre-
travel care were approximately three times more likely to
decline YF vaccination than those travelers who were travel-
ing for non-VFR/non-leisure purposes. VFR travelers, like
other travelers in our study, reported that they sought care at
Table 3
Characteristics or medical conditions of US Global TravEpiNet
travelers visiting areas with YF virus transmission for whom the
provider specified that vaccine was contraindicated (N = 110)
Characteristics or medical conditions* Total (n, %)
Have cancers or blood disorders 19 (17)
Received immune-suppressing
medication/chemotherapy
or took steroids by mouth
in the last 3 months
19 (17)
Other immune system issue(s) 13 (12)
< 6 months old 10 (9)
Pregnant 5 (5)
6–8 months old 4 (4)
³ 60 years 4 (4)
Hypersensitivity to eggs 4 (4)
HIV: most recent CD4 = 200–500 3 (3)
HIV: most recent CD4 < 200 2 (2)
Received organ or bone marrow transplant 1 (1)
Breastfeeding 1 (1)
History of having spleen removed 0 (0)
Thymus disease or history of thymectomy 0 (0)
Analysis includes all travelers visiting areas with risk of YF virus transmission (N = 5,588).
Data on the specific medical conditions were missing for 41 (37%) travelers.
*More than one response allowed.
Table 2
YF vaccination status among US Global TravEpiNet travelers visiting the top 10 countries with risk for YF virus transmission
Destinations
Vaccination administered
with this visit
Reasons for non-vaccination n (row %)
Total
Pre-existing
immunity*
Not indicated
for this itinerary
Referred to primary
care physician
Medical
contraindication
Patient
declined
Insufficient time
to complete
before departure
Vaccine
not available
Entirely endemic
All† 2,244 (69) 664 (21) 76 (2) 8 (< 1) 59 (2) 152 (5) 1 (< 1) 29 (1) 3,233
Tanzania 408 (70) 111 (19) 33 (6) 0 (0) 4 (< 1) 12 (2) 1 (< 1) 10 (2) 579
Kenya 374 (71) 105 (20) 15 (3) 2 (< 1) 9 (2) 22 (4) 0 (0) 0 (0) 527
Ghana 427 (77) 101 (18) 1 (< 1) 3 (< 1) 9 (2) 8 (1) 0 (0) 3 (< 1) 552
Ethiopia 169 (57) 63 (21) 11 (4) 0 (0) 12 (4) 37 (12) 0 (0) 5 (2) 297
Nigeria 145 (58) 66 (26) 0 (0) 0 (0) 5 (2) 32 (13) 0 (0) 2 (1) 250
Uganda 170 (69) 68 (27) 0 (0) 0 (0) 3 (1) 2 (1) 0 (0) 5 (2) 248
Partially endemic
All‡ 963 (75) 234 (18) N/A§ 9 (1) 17 (1) 50 (4) 3 (< 1) 5 (< 1) 1,281
Peru 256 (73) 68 (19) N/A§ 6 (2) 3 (1) 17 (5) 0 (0) 2 (1) 352
Brazil 257 (83) 33 (11) N/A§ 0 (0) 3 (1) 13 (4) 1 (< 1) 0 (0) 307
Ecuador 129 (72) 41 (23) N/A§ 2 (1) 2 (1) 3 (2) 1 (1) 2 (1) 180
Argentina 84 (71) 22 (19) N/A§ 0 (0) 1 (1) 8 (7) 1 (1) 0 (0) 118
Analysis is limited to travelers listing only one destination country (N = 4,518); vaccination status was missing for four travelers.
*Pre-existing immunity is defined as the patient having reported receipt of the YF vaccine within 10 years before the current clinic visit.
†All entirely endemic countries include but are not limited to Tanzania, Kenya, Ghana, Ethiopia, Nigeria, and Uganda.
‡All partially endemic countries include but are not limited to Peru, Brazil, Ecuador, and Argentina.
§Includes those travelers visiting countries where the entire country is considered endemic and/or travelers visiting countries considered partially endemic where the healthcare provider
indicated vaccine might be indicated. Individuals going to partially endemic countries where the healthcare provider chose vaccination not indicated for this itinerary were excluded.
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GTEN clinics, because they were concerned about health
issues or referred to the clinic by their primary care physi-
cians. The finding that VFRs are more likely to decline vacci-
nation underscores the need for both primary care and travel
medicine providers to identify these persons before they
embark on international travel and thoroughly discuss the risk
and benefits of vaccination. Furthermore, VFR travelers
might be more likely to return to the same country in the
future; therefore, providers should discuss the repeated risk
of multiple trips and the value of the vaccine as an investment
in future travel.22 Interestingly, VFR travelers in our study
were more likely to be traveling to Africa.
Our multivariable model also found that travelers to Nigeria
were more likely to decline vaccine. In Nigeria, YF out-
breaks occur frequently.23 A review in 2002 estimated that the
risk of YF illness in travelers to West Africa for a 2-week trip
is 1:2,000 during interepidemic periods and 1:267 during epi-
demic periods, although the risks might vary according to the
season.24,25 Because passive surveillance systems are often
insensitive in identifying cases, the true number of cases is
unknown. Furthermore, the implementation of mass preven-
tive YF vaccination campaigns in certain countries has
increased the proportion of residents with immunity to YF
virus and consequently, led to a decrease in the number of
cases of YF.26 The paucity of reported YF cases in such coun-
tries might falsely reassure travelers, specifically VFR trav-
elers who are still at risk for contracting YF disease if they
have never been immunized.
We also found that females were more likely to decline
vaccine than males after the data were adjusted for age, pur-
pose of travel, duration of travel, destination, and type of
destination. Although the GTEN tool does not collect the
reason for the traveler’s declining recommended vaccination,
possible reasons may include cost, the patient’s perceptions of
the risk of vaccination, or the patient’s perception of the dis-
ease risk from travel (especially in the absence of ongoing
outbreaks).20,27,28
Interestingly, a small percentage of GTEN travelers were
referred to other providers for YF vaccination. Because all
GTEN clinics are designated as YF vaccination centers and
most specialize in travel medicine, it is unclear why these
travelers would have been referred elsewhere. This finding
may reflect intermittent shortages of vaccine. For a number
of travelers, the reported reason for not administering YF
vaccine was vaccine not available. During several months in
2008, Sanofi Pasteur (the sole manufacturer–distributor of YF
vaccine in the United States) reported that single-dose vials of
YF vaccine were in short supply, although five-dose vials were
still available.29 A similar shortage occurred in 2009. Clinics
can monitor national shortages or supply issues through the
US Food and Drug Administration (http://www.fda.gov/
BiologicsBloodVaccines/SafetyAvailability/Shortages/default
.htm) and the CDC (http://www.cdc.gov/vaccines/vac-gen/
shortages). Although logistically difficult, clinics can also arrange
times for multiple travelers to be seen simultaneously for YF
vaccination; this strategy takes advantage of multiple-dose vials
Table 4
Comparison of US Global TravEpiNet travelers who declined versus travelers who were administered YF vaccine before visiting areas with risk
for YF virus transmission
Characteristics
YF vaccine status Bivariate* Multivariable*
Declined (N = 156) N (%) Vaccine administered (N = 2,510) N (%) OR 95% CI OR 95% CI
Age (years)
£ 12† 34 (22) 247 (10) 1.41 0.65–3.06 0.94 0.45–1.96
13–18 10 (6) 150 (6) 0.94 0.33–2.70 0.84 0.32–2.17
19–59 89 (57) 1812 (72) Referent
³ 60 23 (15) 302 (12) 1.42 0.50–4.00 1.55 0.58–4.13
Sex
Female 96 (62) 1,362 (54) Referent Referent
Male 60 (38) 1,149 (46) 0.67 0.43–1.06 0.63 0.41–0.99
Purpose of travel
Leisure 51 (33) 1,172 (47) 1.61 0.96–2.70 1.59 0.86–2.92
VFR‡ 73 (47) 417 (17) 3.02 1.59–5.73 2.57 1.27–5.22
Non-leisure/non-VFR 32 (21) 922 (37) Referent Referent
Duration of travel (days)
£ 14 58 (37) 1,359 (54) Referent Referent
15–30 52 (33) 719 (29) 1.64 0.72–3.72 1.28 0.49–3.31
³ 31 46 (29) 433 (17) 1.21 0.69–2.12 1.02 0.52–1.99
Destinations
Ethiopia 24 (15) 142 (6) 1.83 1.06–3.13 1.43 0.69–2.96
Nigeria 25 (16) 112 (4) 3.39 1.70–6.74 3.01 1.37–6.62
Other countries¶ 107 (69) 2,257 (90) Referent Referent
Type of destinationk
Urban 94 (60) 1,540 (61) Referent Referent
Rural 13 (8) 318 (13) 1.04 0.58–1.88 1.12 0.54–2.30
Both urban and rural 650 (26) 49 (31) 0.74 0.50–1.10 0.72 0.40–1.32
Analysis is limited to travelers who only listed one destination country, listed one purpose of travel, declined vaccine, or were administered vaccine at the clinic visit (N = 2,666).
*Bivariate and multivariable modeling were done using a random intercept model with clinic site as the random effect; a correction was also made to reduce bias caused by small numbers of
clusters (clinic sites).16 There was significant variance attributed by clinic differences on the outcome of receiving or declining YF vaccine (variance = 1.46, standard error = 0.64, P = 0.035).
†Only one traveler under 9 months of age was included in children less than 12 years. For unknown reasons, this child was vaccinated, although YF vaccination is not routinely recommended for
children less than 9 months of age.
‡Travelers participating in GTEN who selected returning to country of origin of self or family to visit friends and relatives and were visiting low or low–middle income countries according to the
2009 World Bank World Development Report (available at http://econ.worldbank.org) were termed VFR travelers as defined previously by the CDC.
§Non-leisure/non-VFR travelers were defined as those travelers traveling for business, adventure, missionary service, non-medical service work, research/education, providing medical care,
receiving medical care, attending a gathering, military, adoption, or self-described other activities.
¶Other countries were defined as all other countries with risk for YF virus transmission except for Ethiopia and Nigeria.
kTravelers could choose more than one answer.
GTEN TRAVELERS TO AREAS WITH RISK OF YF 959
that might be more readily available. Travelers should verify
before their pre-travel consultation that YF vaccine will be avail-
able, if indicated, for their travel.
Our study data were collected before the revised global YF
risk map and country-specific vaccination recommendations
for travelers were published on April 1, 2011.11–13 These rec-
ommendations downgrade Tanzania from a country for which
all travelers had previously been recommended to receive YF
vaccination to one where YF vaccination would be
recommended only for travelers who expect increased risk of
exposure to YF virus because of prolonged travel, heavy
exposure to mosquitoes, or inability to avoid mosquito
bites.11–13 If the revised recommendations had been in effect
during our study period, at least 17% of trips to areas with risk
of YF (e.g., those travelers traveling to Tanzania) captured in
GTENmight have been affected by this change. Although the
GTEN tool does not collect subnational data, future studies
of GTEN data could compare the vaccine status of travelers
to destination countries before and after the change in recom-
mendations and estimate the number of travelers affected.
Our study has a number of limitations. The primary limita-
tion of this study is that it is an analysis of data for individuals
who sought pre-travel advice. Studies have found that most
travelers do not seek pre-travel health advice. One study
conducted at John F. Kennedy International Airport in New
York found that only 36% of travelers sought pre-travel
advice before traveling to high-risk destinations.28 An airport
study at Boston’s Logan International Airport found that only
46% of travelers to low/low–middle income countries sought
pre-travel advice.19 Furthermore, the same study found that,
among travelers to low/low–middle income countries who
sought pre-travel advice, 38% did so from primary care
physicians, and only 30% from travel medicine specialists.19
Considering these findings and the fact that all the GTEN
practices are designated YF vaccination centers, travelers
seeking care at GTEN clinics may not be representative of
the general population of US travelers. YF vaccine is only
authorized to be administered at clinics designated by state
or territorial health departments; such clinics are listed on the
YF Vaccination Center Registry maintained by the CDC and
publicly accessible online (http://www.cdc.gov/travel/yellow-
fever-vaccination-clinics/search.htm). Therefore, travelers plan-
ning to visit countries with YF vaccination requirements or
desiring to comply with CDC’s YF vaccination recommenda-
tions for travel to endemic countries without requirements
must visit one of these designated clinics. The representative-
ness of the GTEN clinics to other clinics listed on the YF
Vaccination Center Registry is unknown; however, GTEN
clinics represent < 1% of all designated YF vaccination centers
in the United States.
Another limitation is that we had to assume that all YF
vaccination decisions made by GTEN clinicians were correct,
because the dataset did not allow us to identify errors in these
decisions. Also, limiting the multivariable analysis to travelers
who listed only one destination and purpose of travel might
have influenced the results. Our results may also have been
influenced by using only low or low–middle income countries
outlined in the 2009 World Bank World Development Report
for the definition of a VFR. Finally, the revised ACIP recom-
mendations for the use of YF vaccine were published in the
middle of our study period (July of 2010) and might have
affected provider and traveler decisions regarding vaccination.2
This study showed that, although most GTEN travelers
visiting areas with risk of YF virus transmission were vacci-
nated at the pre-travel clinic visit or within 10 years before the
clinic visit, VFR travelers, specifically those travelers travel-
ing to Nigeria, were more likely to decline YF vaccination
recommended for their itineraries. Clinicians seeing VFR
travelers should thoroughly discuss destination-specific health
risks, insect bite prevention, and benefits of vaccination, espe-
cially if future travel to areas with risk of YF virus trans-
mission is expected. Travelers should be encouraged to seek
pre-travel consultations 4–6 weeks in advance to allow ade-
quate time for the administration of all other vaccines recom-
mended and ensure that YF vaccine is available. Additional
studies are required to identify travelers’ reasons for declining
recommended YF vaccination and evaluate the effect of the
revised country-specific YF vaccination recommendations
on YF vaccination patterns. Data regarding the reasons for
refusal of YF vaccination by VFR travelers could inform the
development of future outreach and education programs tar-
geted to these travelers.
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